Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective

Ágnes Milassin, Anna Fábián, Tamás Molnár

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Background: Biological therapy has revolutionized the treatment of inflammatory bowel disease (IBD). After the expiration of patents for biological innovator products, development of biosimilars increased. CT-P13 was the first biosimilar approved for the same indications as the reference product; however, the approval was based on extrapolated data from rheumatoid arthritis and ankylosing spondylitis. Our aim was to review clinical studies about switching from originator infliximab (IFX-O) to biosimilar infliximab (IXF-B) in IBD, focusing on recently published data and the future of biosimilars. Methods: The PubMed database was searched for original articles published up to 1 December 2018 reporting data on IFX-B in IBD. Results: A total of 29 studies assessing switching from IFX-O to IFX-B, 14 assessing induction therapy with IFX-B were found. Efficacy, safety and immunogenicity were discussed. Studies confirm that CT-P13 is safe and equally efficient as the reference product for both induction and maintenance therapy; and that switching from the reference product to biosimilar is non-inferior to continuous biosimilar use. However, efficacy and safety data on Flixabi (SB2) in IBD patients is lacking. Conclusion: Switching from the originator to a biosimilar in patients with IBD is acceptable, although scientific and clinical evidence is lacking regarding reverse switching, multiple switching and cross-switching among biosimilars in IBD patients.

Original languageEnglish
JournalTherapeutic Advances in Gastroenterology
Volume12
DOIs
Publication statusPublished - Apr 1 2019

Keywords

  • biosimilar
  • inflammatory bowel disease
  • infliximab
  • switching

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective'. Together they form a unique fingerprint.

  • Cite this